Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 4:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sweating Clear all
Completed Not applicable Interventional

Study on the Effect of NdYag Laser for the Treatment of Hidradenitis Suppurativa

NCT00494351
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Long-pulsed Nd:YAG laser 1064 nm
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Sep 13, 2026, 4:07 AM EDT
Withdrawn Phase 1 Interventional

Allogeneic Micronized Amniotic Membrane Product for the Treatment of Hidradenitis Suppurativa

NCT04541550
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
AMP-001 Low Dose, AMP-001 Medium Dose, AMP-001 High Dose
Drug
Lead sponsor
IntegoGen, LLC
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Sep 13, 2026, 4:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

V2 Receptor Effects on Fluid Regulation and Performance

NCT02084797
View directory record Official record
Conditions
Electrolyte Imbalance, Hyponatremia, Hypernatremia
Interventions
V2R (Vasopressin 2 receptor)
Drug
Lead sponsor
Oakland University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Michigan
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Sep 13, 2026, 4:07 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06212999
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Povorcitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
61
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fort Smith, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 13, 2026, 4:07 AM EDT
Completed No phase listed Observational

Hidradenitis Suppurativa Mail Survey

NCT03572738
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
67 participants
Timeline
2018 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 13, 2026, 4:07 AM EDT
Not listed Phase 2 Interventional

Treatment of Moderate Hidradenitis Suppurativa

NCT03910803
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Brodalumab
Drug
Lead sponsor
Florida Academic Dermatology Centers
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Sep 13, 2026, 4:07 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

An Open Label Study for Palmar Hyperhydrosis

NCT04906655
View directory record Official record
Conditions
Palmar Hyperhidrosis, Hyperhidrosis, Sweat Gland Diseases, Skin Diseases
Interventions
Glycopyrronium 2.4 % Medicated Cloth
Drug
Lead sponsor
Pariser, Robert J., M.D.
Other
Eligibility
9 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Sep 13, 2026, 4:07 AM EDT
Recruiting No phase listed Observational

Biospecimen Analysis in Detecting Chemical Concentrations in Patients With Chronic or Infectious Diseases Receiving Meditations

NCT04160429
View directory record Official record
Conditions
Chronic Disease, Infectious Disorder
Interventions
Biospecimen Collection, Medical Chart Review, Questionnaire Administration
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 13, 2026, 4:07 AM EDT
Recruiting Phase 2 Interventional

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07213973
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Povorcitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Farmington, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 13, 2026, 4:07 AM EDT
Completed Phase 2 Interventional Results available

ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT05216224
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
ATI-450, Placebo oral tablet
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 13, 2026, 4:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sweat Duct Imaging in Mother/Newborn Dyads

NCT01342133
View directory record Official record
Conditions
X-Linked Hypohidrotic Ectodermal Dysplasia
Interventions
Not listed
Lead sponsor
Edimer Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 27, 2012 · Synced Sep 13, 2026, 4:07 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis

NCT02553798
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Glycopyrronium Topical Wipes
Drug
Lead sponsor
Journey Medical Corporation
Industry
Eligibility
9 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
40
States / cities
Mobile, Alabama • Rogers, Arkansas • Encinitas, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Sep 13, 2026, 4:07 AM EDT
Completed Phase 2 Interventional Results available

Dosing Study of Replagal in Patients With Fabry Disease

NCT00068107
View directory record Official record
Conditions
Fabry Disease
Interventions
Replagal
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Sep 13, 2026, 4:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Sunscreen During Exercise Under Conditions of Profuse Sweating (821/2016)

NCT03002922
View directory record Official record
Conditions
Sunscreening Agents
Interventions
BAY987517
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Sep 13, 2026, 4:07 AM EDT
Withdrawn Phase 2 Interventional

Gentian Violet Treatment for Hidradenitis Suppurativa

NCT04388163
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Gentian Violet
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 13, 2026, 4:07 AM EDT
Withdrawn No phase listed Observational

A Single Center, Prospective Clinical Trial of Intravenous Ertapenem in the Treatment of Hurley Stage II or III Hidradenitis Suppurativa

NCT05255575
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Ertapenem
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 13, 2026, 4:07 AM EDT
Completed No phase listed Observational

Collection of Breath and Sweat to Identify Indicators of Hypoglycemia

NCT03600116
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Sep 13, 2026, 4:07 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa

NCT04856930
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Imsidolimab, Placebo
Biological
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
17
States / cities
Birmingham, Alabama • Fountain Valley, California • Northridge, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 13, 2026, 4:07 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)

NCT07155239
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
AviClear Lase Treatment, Sham (No Treatment)
Device
Lead sponsor
Wynn Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rosemead, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 13, 2026, 4:07 AM EDT
Withdrawn Phase 1 Interventional

Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia

NCT00886496
View directory record Official record
Conditions
Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
recombinant human mannose-binding lectin
Biological
Lead sponsor
Enzon Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
3
States / cities
Orange, California • Washington D.C., District of Columbia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 19, 2012 · Synced Sep 13, 2026, 4:07 AM EDT
Withdrawn No phase listed Observational

A Pilot Study to Explore the Role of Gut Flora in Acne

NCT04214483
View directory record Official record
Conditions
Acne, Acne Vulgaris, Acne Keloidalis, Acne Keloid, Acne Conglobata, Acne Rosacea, Acne Inversa, Acne Cystic, Acne Pomade, Acne Indurata, Acne Papular, Acne Tropica, Acne Urticata, Acne Fulminans, Acne Follicular, Acne Tropicalis, Acne Detergicans, Acne Iodide, Acne Varioliformis
Interventions
No intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 13, 2026, 4:07 AM EDT
Active, not recruiting Phase 2 Interventional

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

NCT06993610
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Tibulizumab Dose A, Tibulizumab Dose B, Placebo
Biological · Other
Lead sponsor
Zura Bio Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 13, 2026, 4:07 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

NCT06799000
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • North Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 13, 2026, 4:07 AM EDT
Completed No phase listed Observational

Wound Etiology and Healing Study

NCT01352078
View directory record Official record
Conditions
Wounds, Hidradenitis Suppurativa, Hidradenitis, Acne Inversa
Interventions
Not listed
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 99 Years
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 13, 2026, 4:07 AM EDT